Realm Therapeutics submits IND for PR022 to FDA for atopic dermatitis

US-based biopharmaceutical company Realm Therapeutics has submitted its first investigational new drug (IND) application for PR022 to the US Food and Drug Administration (FDA) for the treatment of patients affected with atopic dermatitis (AD).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news